Isavuconazole provides effective and tolerable antifungal prophylaxis for patients with acute myeloid leukemia
- 28 November 2025
- journal article
- Published by Elsevier in Leukemia Research
- Vol. 160, 108144
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Prospective Pharmacokinetic Evaluation of Venetoclax in AML Supports Re‐Evaluation of Recommended Dose Adjustments With Azole AntifungalsAmerican Journal of Hematology, 2025
- Ivosidenib significantly reduces triazole levels in patients with acute myeloid leukemia and myelodysplastic syndromeCancer, 2024
- Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemmaAnnals of Hematology, 2020
- A Single-Center, Open-Label Trial of Isavuconazole Prophylaxis against Invasive Fungal Infection in Patients Undergoing Allogeneic Hematopoietic Cell TransplantationTransplantation and Cellular Therapy, 2020
- Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignanciesInternational Journal of Antimicrobial Agents, 2017
- Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patientsInfection, 2017
- Oral Azole Antifungal Medications and Risk of Acute Liver Injury, Overall and by Chronic Liver Disease StatusThe American Journal of Medicine, 2016
- Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trialThe Lancet, 2016
- Second- versus first-generation azoles for antifungal prophylaxis in hematology patients: a systematic review and meta-analysisAnnals of Hematology, 2013
- CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancerCancer, 2004